Loading
Life sciences · Journal article
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · November 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background. Drug-induced weight gain is a common adverse effect of many medications used in everyday clinical practice. It contributes to the overall picture of lipid metabolism disorders, may reduce adherence to treatment, including treatment discontinuation with relapse of the underlying disease, and increases the risk of hypertension, type II diabetes mellitus, cardiovascular complications and certain cancers. Objective. To summarize literature data on medications associated with overweight and obesity and to draw clinicians’ attention to drug-related causes of weight gain. Methods. A narrative review of the literature on drug-induced weight gain and obesity. Data on medications, mechanisms of weight gain and clinical consequences were analyzed and summarized. Key content and findings. Glucocorticosteroids, insulin, growth hormone, hormonal contraceptives, psychotropic medications (anticonvulsants, antidepressants, antipsychotics, anxiolytics and sedatives), antihypertensive drugs, antibacterial agents and combination antiretroviral therapy are discussed. Possible mechanisms are considered: increased appetite and altered food preferences, effects on leptin and neuropeptide Y, insulin resistance, reduced physical activity and lipolysis, and influence on the gut microbiota. It is emphasized that drug-induced obesity is not merely a cosmetic issue but is associated with comorbidity and worse prognosis. Conclusions. Drug-induced obesity is a multifactorial condition requiring clinicians’ awareness, timely detection of weight gain during pharmacotherapy and, when necessary, selection of drugs with a more favorable metabolic profile.